Drug Profile


Alternative Names: YKP3089

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator SK biopharmaceuticals
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Anxiolytics; Azoles; Carbamates; Mood stabilisers; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Partial epilepsies
  • Phase II Bipolar disorders; Neuropathic pain
  • Discontinued Anxiety disorders

Most Recent Events

  • 08 Sep 2015 Discontinued - Phase-I for Anxiety disorders (In volunteers) in USA (PO)
  • 21 Aug 2015 SK Life Science plans a phase III trial for Partial epilepsies (Adjunctive treatment) in USA (NCT02535091)
  • 01 Jul 2015 SK Life Science completes a phase II trial in Partial epilepsies (Adjunctive treatment) in the US, Australia, Bulgaria, Czech Republic, France, Germany, Hungary, Israel, South Korea, Poland, Romania, Serbia, Spain, Thailand, Ukraine and the UK (NCT01866111)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top